Centessa Pharmaceuticals plc

Clinical-stage biotech developing OX2R agonists for sleep-wake disorders like narcolepsy and idiopathic hypersomnia. Lead asset: cleminorexton (ORX750) in Phase 2. Nasdaq-listed (CNTA). Being acquired by Eli Lilly.